CA3250467A1 - METHODS FOR CLASSIFYING THE STATE OF DIFFERENTIATION OF CELLS AND ASSOCIATED COMPOSITIONS OF DIFFERENTIATED CELLS - Google Patents

METHODS FOR CLASSIFYING THE STATE OF DIFFERENTIATION OF CELLS AND ASSOCIATED COMPOSITIONS OF DIFFERENTIATED CELLS

Info

Publication number
CA3250467A1
CA3250467A1 CA3250467A CA3250467A CA3250467A1 CA 3250467 A1 CA3250467 A1 CA 3250467A1 CA 3250467 A CA3250467 A CA 3250467A CA 3250467 A CA3250467 A CA 3250467A CA 3250467 A1 CA3250467 A1 CA 3250467A1
Authority
CA
Canada
Prior art keywords
cells
differentiation state
genes
expression levels
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3250467A
Other languages
English (en)
French (fr)
Inventor
Jim Mossman
Derren Barken
Roy Williams
Original Assignee
Aspen Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aspen Neuroscience Inc filed Critical Aspen Neuroscience Inc
Publication of CA3250467A1 publication Critical patent/CA3250467A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Software Systems (AREA)
CA3250467A 2022-04-15 2023-04-14 METHODS FOR CLASSIFYING THE STATE OF DIFFERENTIATION OF CELLS AND ASSOCIATED COMPOSITIONS OF DIFFERENTIATED CELLS Pending CA3250467A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263331783P 2022-04-15 2022-04-15
US63/331,783 2022-04-15
US202263353525P 2022-06-17 2022-06-17
US63/353,525 2022-06-17
PCT/US2023/065811 WO2023201361A1 (en) 2022-04-15 2023-04-14 Methods of classifying the differentiation state of cells and related compositions of differentiated cells

Publications (1)

Publication Number Publication Date
CA3250467A1 true CA3250467A1 (en) 2023-10-19

Family

ID=86329209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3250467A Pending CA3250467A1 (en) 2022-04-15 2023-04-14 METHODS FOR CLASSIFYING THE STATE OF DIFFERENTIATION OF CELLS AND ASSOCIATED COMPOSITIONS OF DIFFERENTIATED CELLS

Country Status (10)

Country Link
US (1) US20230377685A1 (https=)
EP (1) EP4508645A1 (https=)
JP (1) JP2025512442A (https=)
KR (1) KR20250007548A (https=)
CN (1) CN119384700A (https=)
AU (1) AU2023254262A1 (https=)
CA (1) CA3250467A1 (https=)
IL (1) IL316055A (https=)
MX (1) MX2024012742A (https=)
WO (1) WO2023201361A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12565639B2 (en) * 2023-06-13 2026-03-03 Aspen Neuroscience, Inc. Methods for differentiating dopaminergic neurons from stem cells
US20250157580A1 (en) 2023-11-13 2025-05-15 Aspen Neuroscience, Inc. Methods of predicting dopamine production capability of differentiated neuronal cells

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1027211A (en) 1911-03-23 1912-05-21 Robert L Moore Rail-joint.
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
JP4540754B2 (ja) 1996-06-04 2010-09-08 ユニバーシティ オブ ユタ リサーチ ファウンデーション Ｐｃｒ中のハイブリダイゼーションのモニタリング
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
WO2001011011A2 (en) 1999-08-05 2001-02-15 Mcl Llc Multipotent adult stem cells and methods for isolation
WO2001068815A1 (en) 2000-03-14 2001-09-20 Es Cell International Pte Ltd Embryonic stem cells and neural progenitor cells derived therefrom
WO2002014555A2 (en) 2000-08-11 2002-02-21 University Of Utah Research Foundation Single-labeled oligonucleotide probes
ITCZ20020002A1 (it) 2002-04-11 2003-10-13 Parco Scient E Tecnologico Del Dispositivo e metodo per il rilevamento simultaneo di differenti anticorpi e antigeni in campioni clinici, alimentari ed ambientali
EP2929782A1 (en) 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
EP1713903A2 (en) 2004-02-09 2006-10-25 Indiana University Research and Technology Corporation Isolation, expansion and use of clonogenic endothelial progenitor cells
NZ551832A (en) 2004-06-09 2010-01-29 Univ Edinburgh Neural stem cells
US7531355B2 (en) 2005-07-29 2009-05-12 The Regents Of The University Of California Methods and compositions for smooth muscle reconstruction
EP2147094B2 (en) 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
CA2717962C (en) 2008-03-27 2019-05-14 Mount Sinai School Of Medicine Of New York University Human cardiovascular progenitor cells
US8728812B2 (en) 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
JPWO2009148170A1 (ja) 2008-06-06 2011-11-04 独立行政法人理化学研究所 幹細胞の培養方法
AU2009280769B2 (en) 2008-08-13 2014-09-18 Keio University Agent for promoting neuronal differentiation and method therefor
WO2010096496A2 (en) 2009-02-17 2010-08-26 Memorial Sloan-Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
DK3578988T3 (da) 2010-05-25 2025-02-24 Memorial Sloan Kettering Cancer Center Fremgangsmåde til nociceptordifferentiering af humane embryonale stamceller og anvendelse heraf
ES2768229T3 (es) 2010-07-06 2020-06-22 Nanologica Ab Método mejorado para diferenciación de células madre in vivo mediante la administración de morfógenos con sílice mesoporosa y principios activos farmacéuticos correspondientes
WO2012006440A2 (en) 2010-07-07 2012-01-12 Cellular Dynamics International, Inc. Endothelial cell production by programming
MX364742B (es) 2011-01-12 2019-05-07 Tsuneo Kido Metodo de cultivo para obtener y mantener una poblacion pura o enriquecida de celulas no diferenciadas neurales y/o celulas progenitoras neurales de mamifero que con propensas a diferenciarse en celulas del linaje oligodendrocitico in vitro.
WO2012167249A2 (en) 2011-06-02 2012-12-06 Indiana University Research And Technology Corporation Materials and methods for controlling vasculogenesis from endothelial colony forming cells
CN111500665A (zh) 2011-07-21 2020-08-07 小利兰·斯坦福大学托管委员会 来自患者的诱导性多能干细胞的心肌细胞及其使用方法
EP3693455A1 (en) 2011-11-04 2020-08-12 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
EP2614829A1 (en) 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
US9828583B2 (en) 2012-01-13 2017-11-28 The General Hospital Corporation Isolated human lung progenitor cells and uses thereof
WO2014078414A1 (en) 2012-11-13 2014-05-22 Joseph Wu Chemically defined production of cardiomyocytes from pluripotent stem cells
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
EP2951290B1 (en) 2013-02-01 2017-11-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
US20140248696A1 (en) 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
HUE043785T2 (hu) 2013-03-13 2019-09-30 Wisconsin Alumni Res Found Módszerek és anyagok humán pluripotens õssejtek hematoendothelialis differenciálására meghatározott körülmények között
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
EP3498824A1 (en) 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
US11085067B2 (en) * 2013-06-10 2021-08-10 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
KR102611973B1 (ko) 2014-01-14 2023-12-08 예일 유니버시티 기도 세포의 제조를 위한 조성물 및 방법
CA2940691C (en) 2014-03-11 2022-10-25 Indiana University Research And Technology Corporation Method for generating endothelial colony forming cell-like cells
ES2939807T3 (es) 2014-03-21 2023-04-27 Fujifilm Cellular Dynamics Inc Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización
JP6998772B2 (ja) 2015-04-09 2022-02-04 ビオラミナ アーベー 神経変性疾患の処置における使用のための幹細胞由来のドパミン作用性細胞を生成するための方法および組成物
AU2016270793B2 (en) 2015-06-01 2022-06-09 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (MDA) neurons
US20200002679A1 (en) 2018-06-05 2020-01-02 Kcellbio Banking Co., Ltd. Composition for cell regeneration comprising cells hypersecreting growth factors, and at least one of neural stem cells, neurons and gabaergic neurons
JP7810357B2 (ja) * 2019-07-25 2026-02-03 ザ スクリプス リサーチ インスティテュート ドーパミン作動性ニューロン及び前駆細胞を特定する方法
AU2021209068B2 (en) 2020-01-13 2024-09-19 Aspen Neuroscience, Inc. Method of differentiating neural cells and related compositions and methods of use
US20250263752A1 (en) 2020-04-21 2025-08-21 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
WO2021216623A1 (en) 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom

Also Published As

Publication number Publication date
JP2025512442A (ja) 2025-04-17
US20230377685A1 (en) 2023-11-23
IL316055A (en) 2024-11-01
AU2023254262A1 (en) 2024-10-17
KR20250007548A (ko) 2025-01-14
EP4508645A1 (en) 2025-02-19
MX2024012742A (es) 2025-04-02
CN119384700A (zh) 2025-01-28
WO2023201361A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US20240309320A1 (en) Methods for differentiating and screening stem cells
US20200407680A1 (en) Midbrain dopamine (da) neurons for engraftment
JP7810357B2 (ja) ドーパミン作動性ニューロン及び前駆細胞を特定する方法
WO2016103269A1 (en) Populations of neural progenitor cells and methods of producing and using same
US20230377685A1 (en) Methods of classifying the differentiation state of cells and related compositions of differentiated cells
JP7669048B2 (ja) 神経細胞を分化させる方法ならびに関連する組成物および使用方法
US20200397828A1 (en) Atlas of choroid plexus cell types and therapeutic and diagnostic uses thereof
WO2022036158A2 (en) Ex vivo brain tumor model
US20230094922A1 (en) Methods of therapeutic prognostication
US20240329032A1 (en) Methods of differentiating neural cells and predicting engraftment thereof and related compositions
US20250283034A1 (en) Methods for differentiating dopaminergic neurons from stem cells
Metzler et al. A systems biology approach identifies a regulatory network in parotid acinar cell terminal differentiation
EP4357449A1 (en) Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells
US12374424B2 (en) Methods of predicting engraftment capability of differentiated neuronal progenitor cells
Feldman et al. CRISPR-Cas9 screens reveal genes regulating a G0-like state in human neural progenitors
HK40104497A (en) Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells
Wang et al. Kevin Lin, Yue Lu, Collene Jeter, Jianjun Shen, Michelle C. Barton, and Sharon YR Dent

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241010

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250219

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250219

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250403

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260225